Sebacia Postmarket Study of Real-World Use

Status unconfirmed · Not applicable

Conditions studied: Acne Vulgaris

In brief

Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.

Key facts

Study ID

NCT03818555

Run by

Sebacia, Inc.

People needed

125

Starts

2019-01-01

Expected to finish

2021-06-01

Last updated by the study team

2020-10-27

Who can join

Age: 12 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate facial inflammatory acne vulgaris (IGA 2 or 3)
• Between 10 and 50 papules/pustules
• Fitzpatrick skin phototype I, II or III
• Able to provide informed consent and comply with study schedule and other requirements

You may not qualify if…

• Moderately severe or severe acne vulgaris (IGA 4 or 5)
• Nodulocystic acne, significant scarring or excoriation
• Requires oral retinoid, antibiotic or corticosteroid for acne
• New or fluctuating hormone or hormone-regulating therapy
• Photosensitivity or allergy to gold
• Medical or mental health condition that would pose a risk to patient or impair treatment and evaluation

Where it is running

• Miami Dermatology & Laser Institute — Miami, Florida, United States
• Dermatology Institute of Boston — Boston, Massachusetts, United States
• International Clinical Research — Murfreesboro, Tennessee, United States
• Austin Institute for Clinical Research - Central — Austin, Texas, United States
• Austin Institute for Clinical Research - Pflugerville — Pflugerville, Texas, United States
• Premier Clinical Research — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.